TROP-2 in NSCLC

CME

Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 25, 2023

Expiration: July 24, 2024

Hossein Borghaei
Hossein Borghaei, MS, DO
Rebecca S. Heist
Rebecca S. Heist, MD, MPH
Melissa L. Johnson
Melissa L. Johnson, MD
Benjamin Levy
Benjamin Levy, MD
Stephen V. Liu
Stephen V. Liu, MD

Activity

Progress
1
Course Completed

References

  1. Ado-trastuzumab emtansine [prescribing information]. South San Francisco, CA: Genentech; 2022.
  2. Fam-trastuzumab deruxtecan-nxki [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; 2022.
  3. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327-344.
  4. Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173-185.
  5. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
  6. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6:84-105.
  7. Lenárt S, Lenárt P, Šmarda J, et al. Trop2: jack of all trades, master of none. Cancers (Basel). 2020;12:3328.
  8. Lin JC, Wu YY, Wu JY, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012;4:472-485.
  9. Jiang A, Gao X, Zhang D, et al. Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol Lett. 2013;6:375-380.
  10. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8:28725-28735.
  11. Mito R, Matsubara E, Komohara Y, et al. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int. 2020;70:287-294.
  12. Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan-hziy. MAbs. 2019;11:987-995.
  13. Sacituzumab govitecan-hziy [prescribing information]. Foster City, CA: Gilead Sciences; 2023.
  14. Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-2340.
  15. Li BT, Michelini F, Misale S, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020;10:674-687.
  16. Koyama K, Ishikawa H, Abe M, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022;17:e0267027.
  17. Verma S, Breadner D, Raphael J. Targeting improved outcomes with antibody-drug conjugates in non-small cell lung cancer-an updated review. Curr Oncol. 2023;30:4329-4350.
  18. Spitaleri G, Aliaga P, Attili I, et al. Sustained improvement in the management of patients with non-small-cell lung cancer (NSCLC) harboring ALK translocation: where are we running? Curr Oncol. 2023;30:5072-5092.
  19. Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan-hziy, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746-756.
  20. Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan-hziy. J Clin Oncol. 2017;35:2790-2797.
  21. Shimizu T, Sands J, Yoh K, et al. First in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;[Epub ahead of print].
  22. Levy B, Paz-Ares L, Rixe O, et al. TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. Presented at: 2022 International Association for the Study of Lung Cancer World Conference on Lung Cancer; August 6-9, 2022. Abstract MA13.07.
  23. Goto Y, Su WC, Philip B, et al. TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9004.
  24. Pérez-García JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol. 2023;25:157-166.
  25. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
  26. Garon E, Johnson M, Lisberg A, et al. Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase I TROPION-PanTumor01 study. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA49.
  27. Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5:1769-1773.
  28. Oyer RA, Hurley P, Boehmer L, et al. Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. J Clin Oncol. 2022;40:2163-2171.